Tevogen Bio Holdings (TVGN) Operating Income (2023 - 2026)

Tevogen Bio Holdings has reported Operating Income for 4 years, with the latest figure at -$5.4 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income rose 47.85% year-over-year to -$5.4 million; the trailing twelve-month figure through Mar 2026 stood at -$21.2 million (up 38.42% YoY), and the FY2025 full-year result was -$26.1 million, up 51.2% from the prior year.
• Operating Income for Q1 2026 stood at -$5.4 million, down from -$4.6 million in the prior quarter.
• The five-year high for Operating Income was -$2.0 million in Q4 2023, with the low at -$29.5 million in Q1 2024.
• Historically, Operating Income has averaged -$7.2 million across 4 years, with a median of -$5.4 million in 2025.
• Annual changes were most pronounced in 2024 — Operating Income sank 1169.93% — and 2025, when it surged 64.91%.
• Tevogen Bio Holdings' Operating Income stood at -$2.0 million in 2023, then sank by 366.0% to -$9.4 million in 2024, then surged by 50.76% to -$4.6 million in 2025, then slipped by 17.15% to -$5.4 million in 2026.
• The last three Operating Income figures came in at -$5.4 million (Q1 2026), -$4.6 million (Q4 2025), and -$5.7 million (Q3 2025), per Business Quant data.